Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tetracosactide versus betamethasone versus combination therapy for acute gout attacks
2011-000069-11Phase 4Suspended
- Sponsor
- FERNADO PEREZ RUIZ
- Start
- Feb 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in gout comparing Tetracosactide monotherapy, Betamethasone monotherapy and Tetracosactide + betamethasone combination (3 arms). Primary endpoint: Change in patient-assessed pain at 72 hours versus baseline. Started Feb 2011; status: suspended.
02
Drugs
tetracosactide hexaacetatebetamethasone
03
Conditions
gout
Beyond the preview
Go deeper on 2011-000069-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000069-11.